This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements
regarding: the Company’s efforts to continue developing vaccines against COVID-19, including efforts to develop vaccines against variant strains of SARS-CoV-2 and for
updated booster doses; the ability of the Moderna COVID-19 Vaccine to provide protection against COVID-19 over time and to trigger an antibody response against variants
of concern; the Company’s expectations regarding how SARS-CoV-2 will evolve; the conduct and timing of clinical trials for programs in the Company’s pipeline, including its
vaccine candidates against CMV, RSV, Zika, VEGF-A, hMPV + PIV3, HIV, Nipah virus and EBV, as well as the Company’s personalized cancer vaccine candidate; expected timing
for commencement of the Company’s Phase 3 study of its vaccine candidate against seasonal flu; the potential to combine different vaccines into a single dose and to
customize a pan-respiratory vaccine across geography, season and demographics; the potential market opportunity for a pan-respiratory booster vaccine; the construction
of manufacturing facilities in Canada, Africa and Australia, and discussions with other countries regarding in-country mRNA vaccine manufacturing capabilities;
相关推荐
热门下载
推荐
快速链接
热门标签
关注我们
扫码关注我们
了解更多相关信息